Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.
Recently, it has been suggested that the concept of preloading is limited by using a standard amount of unlabeled antibody. To identify the potential of optimal preloading, a pharmacokinetic model that describes the biodistribution of anti-CD20 antibody was developed. Simulations were conducted for different tumor burdens, spleen sizes, and tumor permeabilities. The optimal amount of unlabeled antibody was determined for each scenario. These simulations show that the currently administered standard amount is not optimal. A preload of 150 mg or lower would result in equal or higher tumor uptake in all cases. For tumors with high permeability, the uptake of labeled antibody could be increased by a factor of 8.5 using the considerably reduced optimal preload. The most sensitive parameter for the choice of the optimal amount of unlabeled antibody is the tumor uptake index. The results indicate that a personalized approach for radioimmunotherapy (RIT) with anti-CD20 antibody is required to account for the interpatient variability. The optimal amount of unlabeled antibody, which has to be determined by using a pharmacokinetic model, could substantially improve tumor uptake and thus RIT with anti-CD20 antibody.
Kletting
Peter
P
Klinik für Nuklearmedizin, Universität Ulm, Ulm, Germany.
Meyer
Christoph
C
Reske
Sven N
SN
Glatting
Gerhard
G
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018951:Antigens, CD20 / Q000276:immunology*; D003198:Computer Simulation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D008954:Models, Biological; D057285:Precision Medicine / Q000379:methods; D016499:Radioimmunotherapy / Q000379:methods*; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D047368:Tumor Burden
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20